SARTORIUS STEDIM’S RECOVERY IS DELAYED BUT NOT DERAILED (ADD, 32% UPSIDE)

23/06/26 -" There’s an interesting paradox at the heart of Sartorius Stedim Biotech’s (SSB; ADD; France) investment case. Since our last push in February 2025, the underlying business has done almost everything ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

23/06/26

Download

You may also be interested by these reports :

23/06/26

Idea Kicker

There’s an interesting paradox at the heart of Sartorius Stedim Biotech’s (SSB; ADD; France) investment case. Since our last push in February 2025, ...

03/06/26

Qiagen

Despite a reduction in our target price, as discussed in the EPS section, our positive recommendation on Qiagen remains unchanged. This optimism is ...

29/05/26

Elekta

Elekta’s Q4 results revealed an adjusted EBIT exceeding expectations, although sales fell short. The company offered qualitative guidance for ...

26/05/26

EssilorLuxottica

Piling up assets is no strategy

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue